
|Articles|August 11, 2021
Pharmacy Clinical Pearl of the Day: First-line Treatment Options for Heart Disease
Author(s)Saro Arakelians, PharmD
The goal of treating heart failure is to reduce symptoms, improve heart function, and increase ejection fraction.
Advertisement
Clinical Pearl of the Day:
Heart failure disease first-line treatment options:
- ACE inhibitors/ARB or ARNI (Entresto) and Beta blockers plus aldosterone blockers (for Class II-IV heart failure with GFR>30ml, K+<5)
- SGLT-2 Inhibitor: If volume is overloaded add Loop diuretic
Explanation:
When it comes to heart failure treatment options, patients should be started on beta blockers, ACE inhibitors, ARBs, or ARNIs.
If the dosages are maxed out, patients do not tolerate, or patients do not benefit from these first-line options, then prescribers should be adding aldosterone blockers or SGLT-2 inhibitors
The goal is to reduce the symptoms, improve heart function, and increase ejection fraction.
Advertisement
Related to this article

With a mifepristone safety review due by March and Senate control shifting in January, the FDA faces an extended stretch without a permanent leader.

Pharmacists can help patients start buprenorphine for opioid use disorder by confirming when to take the first dose, whether another opioid continues during initiation, and who will manage symptoms and follow-up.

In older veterans, mRNA-1283 was associated with lower risks of medically attended COVID-19 and hospitalization than BNT162b2.

Pharmacists can use medication therapy management to screen for diabetes, educate patients about medication adherence and lifestyle modifications, and support early action.

In a phase 3 trial of children aged 6 to younger than 12 years, once-weekly semaglutide reduced BMI 16.2 percentage points more than placebo at 68 weeks.

An analysis of 40 economic studies found PCV20 and PCV21 outperformed older strategies, while low uptake and racial gaps limited the benefit of vaccination.
Advertisement
Advertisement
Trending on Pharmacy Times
1
mRNA-1283 Associated With Lower Risk of Medically Attended COVID-19 Than BNT162b2 in Older Veterans
2
Survodutide for Obesity and CV Risk: Liver, Lipids, and Beyond
3
What Pharmacists Should Know About Transitioning Patients to Buprenorphine
4
Long-Acting HIV Injectables in Viremia and New Tenofovir-Free Oral Options
5


